Background. Hepatitis B virus (HBV) modulates microRNA (miRNA) expression to support viral replication. The aim of this study was to identify miRNAs associated with hepatitis B e antigen (HBeAg) status and response to antiviral therapy in patients with chronic hepatitis B (CHB) , and to assess if these miRNAs are actively secreted by hepatoma cells.
The natural course of chronic hepatitis B (CHB) infection is determined by the interplay between hepatitis B virus (HBV) replication and the host immune response. Four phases of CHB infection are identified: the immune-tolerant phase, the immune-reactive hepatitis B e antigen (HBeAg)-positive phase, the inactive HBV carrier state, and HBeAg-negative chronic hepatitis [1] . Antiviral treatment is recommended for CHB patients in the immune-reactive HBeAg-positive phase and patients with HBeAg-negative chronic hepatitis. Current treatment options include pegylated interferon (peg-IFN) and nucleos(t)ide analogues (NUCs). While NUCs efficiently inhibit viral replication, treatment rarely leads to a functional cure (defined as HBsAg loss with or without the formation of anti-hepatitis B surface antigen antibodies) [2] . In peg-IFN-treated patients, a functional cure is only achieved in 3%-7% of patients [3, 4] . Therefore, it is important to identify CHB patients who will benefit from treatment before the start of peg-IFN-based therapy.
MicroRNAs (miRNAs; miR) are small (19-24 nucleotides), noncoding RNA molecules that are involved in various cellular processes. MicroRNAs regulate gene expression at a posttranscriptional level by either blocking messenger RNA (mRNA) translation or inducing its degradation [5] . Levels of circulating miRNAs have been linked to various diseases including viral hepatitis. miR-122 is the most abundant liver-specific miRNA, which plays a central role in liver development and homeostasis [6, 7] , and was found to have a regulatory function in hepatitis C virus (HCV) replication. miR-122 binds to 2 seed sites in the 5′UTR of the HCV genome and promotes HCV RNA accumulation by stabilizing the HCV genome [8] , protects the viral genome from degradation [9] , and increases the rate of viral RNA synthesis [10] . This discovery led to the development of the first successful miRNA-based therapeutic strategy wherein an anti-miRNA silences miR-122 [11] . MicroRNAs may also play a pivotal role in regulating HBV replication. It has been shown that miR-122 inhibits HBV replication by direct binding to the polymerase region of viral transcripts, and antisense inhibition of miR-122 resulted in increased hepatitis B surface antigen (HBsAg) and HBeAg levels in vitro [12] [13] [14] . In addition, targeting of HBV transcripts by other miRNAs has been demonstrated [15] [16] [17] [18] . HBV can regulate miRNA expression and, therefore, the expression of miRNAs supporting viral replication may increase upon infection. Plasma miRNAs can circulate in different conditions: associated with RNA-binding proteins or lipoprotein complexes, but also packaged into microparticles [19] , or HBsAg particles [20] [21] [22] . Indeed, it has been observed that various miRNAs were upregulated in plasma of CHB patients [20, 21] , and that miRNAs could be used as markers predicting treatment response in CHB patients [20, 23] . In our cohort of HBeAg-positive and -negative CHB patients treated with a combination of peg-IFN and adefovir for 48 weeks, a high rate of HBsAg loss was observed (11%-17% at year 2 of treatment-free follow-up) [24] .
The aim of this study was to identify plasma miRNAs that are associated with HBeAg status, HBV DNA, and HBsAg levels, and therapy response to peg-IFN-based treatment in CHB patients. We also aimed to assess if our identified HBVassociated miRNAs are secreted into extracellular vesicles (EVs) and HBsAg particles by hepatoma cells.
METHODS

Study Population
This study was performed in a cohort of 92 CHB patients who participated in an investigator-initiated study (controlled-trials. com; ISRCTN 77073364), which has been described in detail previously [24] . All patients gave written informed consent. In summary, patients were documented to be HBsAg-positive for >6 months, were either HBeAg-positive or -negative, and had HBV DNA levels >17 182 IU/mL (100 000 copies/mL). Patients received a combination of peg-IFN alfa-2a 180 μg subcutaneously once a week, and adefovir dipivoxil 10 mg daily. Several biochemical and virological analyses were conducted, including measurement of alanine aminotransferase (ALT), HBsAg, HBeAg, and HBV DNA levels [24] . Therapy response was determined after 6 months (week 72) and 2 years (week 144) of treatment-free follow-up. Combined response was defined as the combination of a virological (HBeAg negativity, and HBV DNA levels ≤2000 IU/mL) and a biochemical response (persistent normal ALT levels) in both HBeAg-positive and -negative patients, according to European Association for the Study of the Liver guidelines [25] . HBsAg loss was defined as all above criteria for combined response plus HBsAg level <0.05 IU/mL (Abbott AxSYM). Eighty-six patients completed 48 weeks of treatment and follow-up of 2 years and fulfilled the inclusion criteria for the present study. We selected 12 HBeAg-positive and 12 HBeAg-negative patients as an identification cohort, both consisting of 6 combined responders, of which 3 patients had HBsAg loss, and 6 nonresponders (Supplementary Figure 1A) .
Current Study Design
This study was comprised of 3 steps: (1) Identification of HBVassociated miRNAs in an identification cohort of 24 CHB patients. MicroRNAs with >2-or 3-fold change and P < .1 between HBeAg-positive vs -negative patients, or responders vs nonresponders, were selected for analysis in (2) confirmation analysis of candidate miRNAs in confirmation cohort of 64 CHB patients (HBeAg-positive and -negative, and responders and nonresponders) and 10 healthy controls (n = 10) (Supplementary Figure 1B) ; (3) proof-of-concept study to assess if our HBV-associated miRNAs in (1) and (2) are actively secreted by measuring miRNA levels in hepatoma cells, culture supernatant, EVs, and HBsAg particles.
Plasma miRNA Isolation
From pretreatment plasma samples, RNA was isolated with the miRCURY RNA isolation kit (Exiqon) according to the manufacturer's protocol. Synthetic cel-miR-39 (Qiagen) was spiked into the lysis buffer to check RNA isolation efficiency. RNA samples were stored at -80°C.
Cell and Culture Conditions
MicroRNA levels were analysed in the hepatoma cell lines HepG2 and HepG2 2.2.15. HepG2.2.15 cells are stably transfected with the HBV genome and produce Dane particles, as well as HBeAg, HBsAg, and HBV core particles [26] . HepG2 and HepG2.2.15 cells were cultured at 37°C and 10% CO 2 . Culturing was performed in William's medium E (Lonza, Basel, Switzerland) supplemented with 10% (v/v) heat-inactivated fetal calf serum, l-glutamine, dexamethasone, penicillin (100 U/ mL), and streptomycin (100 μg/mL). MicroRNA was extracted from cells and culture supernatant with the miRNeasy mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. EVs and HBsAg isolation from culture supernatant was performed with ultracentrifugation followed by immunoprecipitation using αCD63 or αPre-S1 antibodies and protein G magnetic beads (Supplementary Methods).
Complementary DNA Synthesis and Reverse-Transcription Quantitative
Polymerase Chain Reaction
Complementary DNA (cDNA) was synthesized using qScript mRNA cDNA synthesis kit (Quanta Biosciences) and miR-CURY LNA Universal RT cDNA synthesis Kit (Exiqon). A serum/plasma focus microRNA quantitative polymerase chain reaction (qPCR) panel (Exiqon) was used to determine the expression level of 179 different miRNAs in the identification cohort. Individual miRNA reverse-transcription qPCR (RT-qPCR) was performed using LightCycler 480 SYBR Green I Master (Roche Diagnostics). To determine the absolute copy numbers of miRNAs of interest in HepG2 and HepG2.2.15 cells, standard curves were constructed (Supplementary Methods).
Data Analysis
The amplification curves of miRNAs were analyzed using the Lightcycler 480 Software (Roche Diagnostics) for the quantification of cycles (Cq) and for the melting curve analysis. All assays were inspected for distinct melting curves. Data were preprocessed using GenEx pro software (MultiD Analyses). Suitable reference genes (miR-93-5p and miR-425-5p) were found by applying the NormFinder and GeNorm algorithms on the plasma miRNA profile panel results [27, 28] . Plasma miRNAs were normalized using the ∆Cq method (Cq miRNA of interest -arithmetic mean Cq miR-93-5p and miR-425-5p) [29] . The normalized individual data points are presented as the log 10 2 ^ -∆Cq. The difference in expression level of miRNAs between study groups was calculated with the comparative Cq-method (2 ^ -((Cq miRNA of interest group A -arithmetic mean Cq miR-93-5p and miR-425-5p group A) -(Cq miRNA of interest group B -arithmetic mean Cq miR-93-5p and miR-425-5p group B))) and expressed as the fold change level. [29] We tested for difference in miRNA levels between study groups and hepatoma cell lines using the Student t test or Mann-Whitney U test, and one-way analysis of variance with posttest for linear trend using SPSS (version 23) and GraphPad software (version 7.0). Correlations were analyzed with Pearson correlation coefficient (r) using SPSS (version 23). Unsupervised hierarchical clustering was performed with GenePattern software.
RESULTS
Patient Characteristics
Baseline characteristics of patients included in the identification cohort (n = 24) and confirmation cohort (n = 62) are summarized in Table 1 . Patients were HBeAg-positive (n = 41) or HBeAg-negative (n = 45). At week 72, 31 of 86 (36%) patients had combined response. At week 144, 13 of 86 (15%) patients had HBsAg loss.
Identification of Candidate miRNAs
A plasma miRNA profile of 179 miRNAs was determined in the identification cohort of 12 HBeAg-positive and 12
HBeAg-negative patients, both groups consisted of 6 responders, of which 3 patients had HBsAg loss, and 6 nonresponders (Supplementary Figure 1A) . Nine miRNAs (miR-122-5p, miR-125b-5p, miR-127-3p, miR-192-5p, miR-193b-3p, miR-194-5p, miR-200a-3p, miR-204-5p, and miR-29a-5p) were differentially expressed (>3-fold) between HBeAg-negative and -positive patients and met selection criteria to be analyzed in the confirmation cohort (Supplementary Table 1 ). In HBeAg-positive patients, 3 miRNAs (miR-132-3p, miR-145-5p, miR-301a-3p) were differentially expressed (>2-fold) between responders (combined response and/or HBsAg loss) and nonresponders and met selection criteria to be analyzed in the confirmation cohort (Supplementary Table 2 ). In HBeAg-negative patients, 18 miRNAs (let-7d-3p, let-7e-5p, miR-106b-3p, miR-10b-5p, miR-125b-5p, miR-141-3p, miR-143-3p, miR-145-5p, miR-146b-5p, miR-17-5p, miR193b-3p, miR-194-5p, miR-215, miR-30c-5p, miR-30e-3p, miR-326, miR-361-3p, and miR-485-3p) were differentially expressed (>2-fold) between responders (combined response and/or HBsAg loss) and nonresponders and met selection criteria to be further analyzed in the confirmation cohort (Supplementary Table 2 ). In total, we identified 26 miRNAs associated with HBeAg status and/or treatment response in a cohort of 24 CHB patients.
Higher Plasma Levels of HBV-Associated miRNAs in CHB Patients Versus Healthy Controls
Of 26 previously identified HBV-associated miRNAs, relative plasma levels of 16 miRNAs were significantly higher in CHB patients (n = 86, identification and confirmation cohort) compared to healthy controls (n = 10) (Supplementary Table 3) . CHB patients had 59-fold higher mean plasma levels of miR-122-5p compared to healthy controls (P < .001). In addition, plasma levels were 24-fold higher in CHB patients for miR-192-5p, 20-fold higher for miR-193b-3p, 38-fold higher for miR-194-5p, and 24-fold higher for miR-215 compared to healthy controls, all P < .001 (Supplementary Table 3 ). Unsupervised hierarchical clustering using the 16 highly significant (P < .001) Data shown as mean ± standard deviation unless otherwise indicated.
Abbreviations: ALT, alanine aminotransferase; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus.
differentially expressed miRNAs clustered all healthy controls together ( Figure 1 ).
Different miRNA Signature in HBeAg-Positive and -Negative CHB
Patients
Plasma levels of the 9 miRNAs (miR-122-5p, miR-125b-5p, miR-127-3p, miR-192-5p, miR-193b-3p, miR-194-5p, miR200a-3p, miR-204-5p, and miR-29a-5p) with differential expression between HBeAg-positive and negative CHB patients in the identification cohort (n = 24), were measured in the confirmation cohort (n = 62 CHB patients) (Supplementary Figure 1B) and compared between HBeAg-positive (n = 29) and HBeAg-negative (n = 33) patients. HBeAg-positive patients had significant higher plasma levels of miR-125b-5p (2.2-fold, P = .004), miR-192-5p (2.1-fold, P = .022), and miR-194-5p (3.4-fold, P = .001) compared to HBeAg-negative patients ( Table 2 ). Plasma levels of miR-122-5p and miR-193b-3p were >1.5-fold higher in HBeAg-positive patients, but these differences were not statistically significant (1.8-fold, P = .083 and 1.6-fold, P = .089, respectively). Plasma levels of miR-127-3p, miR-200a-3p, miR-204-5p and miR-29a-5p were not different between HBeAg-positive and -negative patients (fold change level > -1.5 and <1.5; P > .05) ( Table 2) . A significant increasing trend of all miRNA levels (except for miR-127-3p) was observed from healthy controls to HBeAg-negative patients to HBeAgpositive patients (Figure 2 ). Analysis of plasma miRNA levels of the total cohort (n = 86) showed a similar pattern as seen in the confirmation cohort, with the addition of a significant higher miR-122-5p and miR-193b-3p level in HBeAg-positive patients (Table 2) . Next, we analyzed whether plasma miRNA levels were associated with HBV DNA level, HBsAg level, and ALT level. A correlation was found between plasma miRNA levels (miR-122-5p, miR-125b-5p, miR-192-5p, miR-193b-3p, miR-194-5p, and miR-29a-5p) and both HBV DNA and HBsAg levels ( Figure 3 ). However, ALT levels were only correlated with plasma miR-193b-3p levels ( Figure 3 ).
Concluding, we observed a differential plasma miRNAs signature between HBeAg-positive and -negative patients, and found that various of these miRNAs are correlated with HBV DNA and HBsAg levels.
Higher Baseline Plasma Level of miR-301a-3p and miR-145-5p in
Responders Versus Nonresponders
Baseline plasma levels of miR-132-3p, miR-145-5p, and miR301a-3p were measured in all HBeAg-positive patients (n = 41) and compared between patients with combined response (n = 14) and nonresponse (n = 27) at week 72, and between patients with HBsAg loss (n = 5) and nonresponse (n = 29) at week 144. Plasma miR-301a-3p levels were 1.8-fold (P = .002) and 1.6-fold (P = .088) higher in HBeAg-positive patients with combined response and HBsAg loss compared to nonresponders, respectively (Table 3) . Plasma miR-132-3p and miR-145-5p levels were lower in HBeAg-positive responders vs nonresponders, but this difference was not significant (Table 3 ). In total, 18 candidate miRNAs were measured in all HBeAg-negative patients (n = 45) and compared between responders (combined response and/or HBsAg loss) and nonresponders. miR-145-5p was 1.5-fold (P = .028) higher in HBeAg-negative patients with HBsAg loss compared to nonresponders at week 144 (Table 3 ). All other miRNA levels (n = 17) were not different (fold change level > -1.5 and <1.5; P > .05) between HBeAg-negative responders and nonresponders (Table 3) . Taken together, we showed that pretreatment plasma miR-301a-3p level was higher in HBeAg-positive patients with combined response compared to nonresponders, and that plasma miR-145-5p level was higher in HBeAg-negative patients with HBsAg loss.
Identification and Secretion of HBV-Associated miRNAs in Hepatoma Cell Lines
As a proof-of-concept study, levels of our identified HBVassociated miRNAs were measured in HepG2 and HepG2.2.15 cells, culture supernatant, EVs, and HBsAg particles. For this analysis, we selected 5 miRNAs (miR-122-5p, miR-125b-5p, miR-192-5p, miR-193b-3p, and miR-194-5p), which were all significantly upregulated in CHB patients vs healthy controls, and in HBeAg-positive vs -negative patients (Table 2  and Supplementary Table 3 ). In HepG2.2.15 cells, mean HBV DNA level was 4.3 log 10 copies in intracellular viral capsids, and 2.72 log 10 copies in culture supernatant, demonstrating active HBV replication (Supplementary Figure 2) . miR-122-5p and miR-125b-5p showed low expression in both HepG2 and HepG2.2.15 cells (Supplementary Table 4 and Figure 4A ) [30] . miR-192-5p, miR-193b-3p, and miR-194-5p were expressed in both HepG2 and HepG2.2.15 cell lines (Supplementary  Table 4 and Figure 4B-D Table 4 and Figure 4B and 4C). In contrast, miR-194-5p level was significantly higher in EVs secreted by HepG2.215 cells compared to HepG2 cells (1.66 log 10 copies/total RNA vs 0.57 log 10 copies/total RNA; P = .02). miR-192-5p, miR-193b-3p, and miR-194-5p levels were all present in HBsAg particles secreted by HepG2.2.15 cells (Figure 4B-D) . One-way analysis of variance with a posttest for linear trend was used to compare the different groups. **P < .01; ***P < .001; ****P < .0001; ns, not significant.
DISCUSSION
In this study, we showed that HBeAg-positive patients have higher plasma levels of 5 miRNAs (miR-122-5p, miR-125b-5p, miR-192-5p, miR-193b-3p, and miR-194-5p) compared to HBeAg-negative patients and that levels of these miRNAs were associated with HBV DNA and HBsAg levels, indicating a relation with viral replication. Furthermore, we found that pretreatment plasma levels of miR-301a-3p and miR-145-5p were higher in CHB patients who achieved combined response or HBsAg loss following peg-IFN/nucleotide analogue therapy compared to nonresponders. As a proof-of-concept study, we showed that miR-192-5p, miR-193b-3p, and miR-194-5p levels were present in EVs and HBsAg particles of hepatoma cell line with and without active HBV replication, which might suggest active packaging and secretion of these miRNAs. Similar to previous studies, we showed that plasma miR-122 levels were approximately 60-fold higher in CHB patients compared to healthy controls, and approximately 2-fold higher in HBeAg-positive patients vs HBeAg-negative patients [31] [32] [33] . Surrogate parameters for HBV replication and translation, namely HBV DNA and HBsAg levels, were positively correlated with plasma miR-122 levels. Increases in circulating miR-122 levels in plasma might be caused by HBV-induced upregulation of miR-122 expression and thus increased secretion from the liver. Variations of serum miRNA profiles between CHB patients and healthy controls and across the different phases of CHB infection were observed in previous studies and partly confirm our findings [20, 34, 35] . We showed that plasma miR-125b-5p levels are approximately 5-fold higher in CHB patients vs healthy controls, and approximately 2-fold higher in HBeAg-positive vs -negative patients. miR-125b-5p was previously associated with direct and indirect downregulation of HBV [34, 36] . In addition, miR-125b-5p has been shown to suppress other virus infections as well as tumorigenesis [37, 38] . This might indicate that miR-125b-5p may be part of the innate protection of the host against viral infection. We observed that plasma levels of miR-192-5p, miR-193b-3p, miR-194-5p, and miR-215 were all highly upregulated (≥20-fold) in CHB patients compared to healthy controls. Interestingly, 3 of these miRNAs are encoded in clusters: the miR-215/miR-194-1 cluster on chromosome 1 (1q41) and the miR-192/miR-194-2 cluster on chromosome 11 (11q13.1) [39] . MicroRNA members of the same cluster are usually co-expressed and co-regulated and may target the same molecule or hit several molecules in the same biological pathways. Downregulation of these 3 miRNAs was previously reported in various types of cancer [39, 40] . In addition, an upregulation of miR-194-5p levels in HBeAgpositive patients compared to healthy controls and HBeAgnegative patients was previously described [35] . In this study, we observed higher pretreatment plasma miR301a-3p levels in HBeAg-positive patients who received combination therapy and who developed combined response at week 72 compared to nonresponders. Also, we showed that high pretreatment plasma miR-145-5p level was significantly associated with HBsAg loss in HBeAg-negative patients. Although miR-301a-3p and miR-145-5p have been associated with other liver diseases such as nonalcoholic fatty liver disease and HBV-induced hepatocellular carcinoma [41] [42] [43] , our study is the first to identify miR-301a-3p and miR-145-5p as potential pretreatment response markers for treatment outcome in CHB patients. Previously, it was demonstrated that baseline miR-122 levels were significantly lower in HBV/HCV-coinfected patients treated with peg-IFN and ribavirin who cleared HBsAg than in patients who did not [23] . Although we did observe a >3-fold lower baseline miR-122 level in CHB patients with HBsAg loss in the identification cohort, this difference was not significant and therefore not further assessed in the confirmation cohort.
It was shown that nearly 90% of the total miRNAs in the liver are comprised of approximately 10 miRNAs (of which miR-122 is the major contributor with 50%-70% of the miRNA profile) [44] . Following miR-122, miR-192-5p was the most abundantly expressed miRNA in the human liver, and except for miR-301a-3p, all our other identified HBV-associated miRNAs were found to be expressed in liver tissue [45] . A broad miRNA expression profiling study revealed miR-301a-3p expression in various tumor tissues, hepatic stellate cells, and immune cells [46] . In addition, it was shown that miR-301a-3p was expressed in HepG2.2.15 cells and not in HepG2 cells, suggesting a possible relation with HBV [46] . In this study we have measured circulating miRNA levels instead of hepatic miRNA levels, and the functions of plasma miRNAs have been debated. Several studies suggest that plasma miRNAs do not have any biological function and are byproducts of dying cells. However, miRNAs can also be actively secreted and used for intercell communication [47] , and it was shown that viruses can actively package miRNAs into EVs and transfer them to uninfected cells and thereby support viral replication and/or induce an innate immune response [48, 49] . In CHB patients, it was previously demonstrated that circulating subviral HBsAg particles carry host cellular miRNAs [20] [21] [22] 35] . In cell lines, we investigated in a proof-of-concept study if our plasma HBV-associated miRNAs were actively packaged and secreted. We measured miRNA levels in 2 hepatoma cell lines including a cell line which is stably expressing HBV infection (HepG2.2.15). The presence of miRNAs in the culture supernatant could suggest that miRNAs are actively secreted by hepatoma cells. We could not assess secretion of miR-122-5p and miR-125b-5p in HepG2 and HepG2.2.15 cells as these miRNAs were expressed at very low levels. This can be explained by translational repression of the miR-122 gene by reduced accessibility of chromatin of hepatocyte nuclear factor 4-alpha (HNF4α) in the HepG2 promotor [30] .We found that miR-192-5p and miR-194-5p were more highly expressed in HepG2.2.15 cells compared to HepG2 cells. The higher expression of miR-192-5p may be caused by the HBx-induced expression of growth factor β-1, which in turn could lead to the upregulation of miR-192 [50] . The secretion and active packaging of miR-194-5p into EVs was significantly higher for HepG2.2.15 (with HBV) compared to HepG2 (without HBV) cells. This finding was in line with our previous observation that CHB patients had higher plasma miR-194-5p levels compared to healthy controls.
Because current treatment options for CHB patients rarely achieve a functional cure, there is a need for new therapeutic options. Our identified HBV-associated miRNAs may play a functional role in HBV replication by direct targeting of viral transcripts or cellular factors required for HBV replication, or be related to immune functions. Future studies should aim to identify links between miRNAs, their putative targets, and HBV replication. If miRNAs are shown to have a direct or indirect role in the regulation of HBV replication, these miRNAs would be attractive novel targets for CHB treatment. In addition, circulating miRNAs could serve as potential biomarkers for CHB disease stage or to predict response to antiviral treatment.
To conclude, we have identified miRNAs that are associated with HBeAg status, HBV DNA and HBsAg levels, and treatment response in CHB patients. We demonstrated that various of these HBV-associated miRNAs are secreted into EVs and HBsAg particles derived from cells stably transfected with a complete HBV genome.
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